GQ-1005

N/A

Report date: 2024/12/25 20:00:50

Base Information

Drug NameGQ-1005
Drug Alias NameGQ-1005GQ1005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGeneQuantum Healthcare (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGeneQuantum Healthcare (Suzhou) Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A